Skip to main content

Advertisement

Table 6 Multivariate analysis of ABCG2 promoter methylation and its association with the overall survival of GBM patients

From: Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme

Variable Haz. ratio p-value [95% Conf. Interval]
Sex    
male 1.463 0.271 0.743 2.879
(ref. female) 1.092 0.842 0.459 2.600
2.489 0.211 0.596 10.389
Age     
50- < 60 years 1.745 0.317 0.586 5.195
(ref. <50 years) 1.454 0.545 0.433 4.882
1.552 0.760 0.092 26.033
Age     
60- < 70 years 2.270 0.085 0.892 5.778
(ref. <50 years) 2.271 0.118 0.811 6.358
1.068 0.957 0.102 11.210
Age     
≥70 years 6.112 0.001 2.087 17.903
(ref. <50 years) 9.923 0.000 2.808 35.062
2.774 0.376 0.290 26.572
Mean methylation level (Continuous)     
1.003 0.736 0.986 1.021
0.998 0.836 0.977 1.019
  1.018 0.430 0.974 1.065
  1. Continuous multivariate Cox model regression analysis of ABCG2 promoter methylation and its association with the overall survival (OS) of the analyzed patients with glioblastoma multiforme, adjusted for potential risk factors including sex and age at diagnosis and stratified on the variable therapy. Normal typed data: the entire glioblastoma cohort; Italic data: Temozolomide treated glioblastoma patients; Bold face data: Glioblastoma patients without temozolomide treatment (Haz. Ratio, Hazard Ratio; Conf. Interval, Confidence Interval).